EUVIMEDEUVIMED entdecken
EditorialKommentarOpen Access

KRAS G12C mutation: from undruggable target to potentially agnostic biomarker

Badi El Osta

Translational Lung Cancer Research · 2023-06 · 12 (6) · 1147-1151

DOI: 10.21037/tlcr-23-174 ↗

Kurz gefasst

Editorial in der Zeitschrift Translational Lung Cancer Research, 2023-06. Verfasst von Badi El Osta. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mutation who were previously treated with a platinum-based regimen and a programmed cell death 1 ( PD - 1 ) or programmed cell death ligand 1 ( PD - L1 ) immune checkpoint inhibitor (ICI) ( Table 1 ). In addition, adagrasib showed excellent central nervous system (CNS) penetration and activity on untreated brain metastases in these patients with a response rate of 33% (5) and unbound brain to unbound plasma concentration ratio ( K p,uu ) comparable to osimertinib (8) and therefore warrant testing in treatment naïve patients with KRAS mutant NSCLC with brain metastases. Of note, outcomes outside CNS were not as striking as the one seen with current EGFR and ALK inhibitors and therefore warrant optimizing future KRAS G12C inhibitors target effect in addition to ongoing

Schlagwörter

Stichwörter der Autor:innen

Kristen rat sarcoma (KRAS)Non-small cell lung cancers (NSCLC)precision oncologytargeted therapy

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
  • Atlanta VA Medical Center, Decatur, GA, USA.
  • Winship Cancer Institute of Emory University, Atlanta, GA, USA.

Zitieren

APA

El Osta, B. (2023). KRAS G12C mutation: from undruggable target to potentially agnostic biomarker. Translational Lung Cancer Research, 12(6), 1147-1151. https://doi.org/10.21037/tlcr-23-174

Vancouver

El Osta B. KRAS G12C mutation: from undruggable target to potentially agnostic biomarker. Translational Lung Cancer Research. 2023;12(6):1147-1151. doi:10.21037/tlcr-23-174

BibTeX
@article{ElOsta2023,
  author = {El Osta, Badi},
  title = {KRAS G12C mutation: from undruggable target to potentially agnostic biomarker},
  journal = {Translational Lung Cancer Research},
  year = {2023},
  volume = {12},
  number = {6},
  pages = {1147--1151},
  doi = {10.21037/tlcr-23-174}
}
Kostenlos starten →